fbpx Skip to main content

OBI-999 monotherapy was determined to be well-tolerated and safe for patients with advanced solid tumors; however, it was associated with dose-limiting non-cumulative neutropenia.

OBI-999 is a new antibody–drug conjugate comprising the Globo H-targeting antibody, OBI-999, combined with cytotoxic monomethyl auristatin E (MMAE). This study demonstrated that the drug was well-tolerated in patients with advanced solid tumors, in doses up to 1.2 mg/kg, which is the recommended dose for phase II of the study. The drug was administered once every three weeks and was associated with dose-limiting non-cumulative neutropenia. The study findings are published in JCO Precision Oncology.

OBI-999 Demonstrated Non-Linear Pharmacokinetics

This first-in-human sequential dose-escalation study demonstrated non-linear pharmacokinetics for OBI-999 in doses ranging from 0.4 to 1.6 mg/kg. The drug had lower clearance at comparatively higher doses. The levels of MMAE in the circulation were low compared to the antibody–drug conjugate; however, there was a disproportionate increase in the MMAE exposure in the 1.6 mg/kg drug cohort.

Treatment-Emergent Adverse Events in OBI-999 Administration

The most prevalent treatment-emergent adverse events observed throughout the study were anemia and neutropenia in patients with advanced solid tumors, with the majority of the TEAEs being moderate or mild in severity. OBI-999 was found to be safe and well-tolerated in study participants at a dose level of 1.2 mg/kg. However, patients treated at a 1.6 mg/kg dose level demonstrated grade 4 neutropenia.

OBI-999 monotherapy was found to be well-tolerated and safe for patients with advanced solid tumors at a once per three weeks dose of 1.2 mg/kg, without any significant adverse effects, except for dose-limiting non-cumulative neutropenia.

You May Also Like::  Does DECR1 Regulate PUFA oxidation to Protect Prostate Tumor Cells from Ferroptosis

Source:

Tsimberidou, A. M., Vo, H. H., Beck, J., Shia, C. S., Hsu, P., & Pearce, T. E. (2023). First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. JCO Precis Oncol, 7, e2200496. https://doi.org/10.1200/po.22.00496

 

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.

#dermtwitter
@AADmember

New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More